Dysregulation of the IL-13 receptor system: a novel pathomechanism in pulmonary arterial hypertension.

RATIONALE Idiopathic pulmonary arterial hypertension (IPAH) is characterized by medial hypertrophy due to pulmonary artery smooth muscle cell (paSMC) hyperplasia. Inflammation is proposed to play a role in vessel remodeling associated with IPAH. IL-13 is emerging as a regulator of tissue remodeling; however, the contribution of the IL-13 system to IPAH has not been assessed. OBJECTIVES The objective of this study was to assess the possible contribution of the IL-13 system to IPAH. METHODS Expression and localization of IL-13, and IL-13 receptors IL-4R, IL-13Rα1, and IL-13Rα2 were assessed by real-time reverse transcription-polymerase chain reaction, immunohistochemistry, and flow cytometry in lung tissue, paSMC, and microdissected vascular lesions from patients with IPAH, and in lung tissue from rodents with hypoxia- or monocrotaline-induced pulmonary hypertension. A whole-genome microarray analysis was used to study IL-13-regulated genes in paSMC. MEASUREMENTS AND MAIN RESULTS Pulmonary expression of the IL-13 decoy receptor IL-13Rα2 was up-regulated relative to that of the IL-13 signaling receptors IL-4R and IL-13Rα1 in patients with IPAH and in two animal models of IPAH. IL-13, signaling via STAT3 and STAT6, suppressed proliferation of paSMC by promoting G(0)/G(1) arrest. Whole-genome microarrays revealed that IL-13 suppressed endothelin-1 production by paSMC, suggesting that IL-13 controlled paSMC growth by regulating endothelin production. Ectopic expression of the il13ra2 gene resulted in partial loss of paSMC growth control by IL-13 and blunted IL-13 suppression of endothelin-1 production by paSMC, whereas small-interfering RNA knockdown of il13ra2 gene expression had the opposite effects. CONCLUSIONS The IL-13 system is a novel regulator of paSMC growth. Dysregulation of IL-13 receptor expression in IPAH may partially underlie smooth muscle hypertrophy associated with pathological vascular remodeling in IPAH.

[1]  M. Humbert,et al.  Inflammation in pulmonary arterial hypertension , 2003, European Respiratory Journal.

[2]  W. Seeger,et al.  The noncanonical WNT pathway is operative in idiopathic pulmonary arterial hypertension. , 2009, American journal of respiratory cell and molecular biology.

[3]  S. Abman.  Role of endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. , 2009, Annual review of medicine.

[4]  W. Seeger,et al.  Transcriptome profiling of primary murine monocytes, lung macrophages and lung dendritic cells reveals a distinct expression of genes involved in cell trafficking , 2009, Respiratory research.

[5]  Therapeutics targeting IL-13 for the treatment of pulmonary inflammation and airway remodeling. , 2008, Current opinion in investigational drugs.

[6]  M. Wilkins,et al.  Emerging concepts and translational priorities in pulmonary arterial hypertension. , 2008, Circulation.

[7]  W. Seeger,et al.  Fhl-1, a New Key Protein in Pulmonary Hypertension , 2008, Circulation.

[8]  M. Lederman,et al.  Pulmonary arterial hypertension and its association with HIV infection: an overview , 2008, AIDS.

[9]  Douglas K. Miller,et al.  IL-13 as a therapeutic target for respiratory disease. , 2008, Biochemical pharmacology.

[10]  Guoyao Wu,et al.  IL-4 and IL-13 upregulate ornithine decarboxylase expression by PI3K and MAP kinase pathways in vascular smooth muscle cells. , 2008, American journal of physiology. Cell physiology.

[11]  V. Kurup,et al.  Pulmonary arterial remodeling induced by a Th2 immune response , 2008, The Journal of experimental medicine.

[12]  R. Homer,et al.  IL-13 Receptor α2 Selectively Inhibits IL-13-Induced Responses in the Murine Lung1 , 2008, The Journal of Immunology.

[13]  R. Speich,et al.  Increased Regulatory and Decreased CD8+ Cytotoxic T Cells in the Blood of Patients with Idiopathic Pulmonary Arterial Hypertension , 2007, Respiration.

[14]  M. Humbert,et al.  Role of endothelium-derived CC chemokine ligand 2 in idiopathic pulmonary arterial hypertension. , 2007, American journal of respiratory and critical care medicine.

[15]  O. Eickelberg,et al.  Transforming growth factor beta/bone morphogenic protein signaling in pulmonary arterial hypertension: remodeling revisited. , 2007, Trends in cardiovascular medicine.

[16]  W. Seeger,et al.  Hypoxia-Dependent Regulation of Nonphagocytic NADPH Oxidase Subunit NOX4 in the Pulmonary Vasculature , 2007, Circulation research.

[17]  S. Archer,et al.  The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted , 2007, Proceedings of the National Academy of Sciences.

[18]  N. Voelkel,et al.  Absence of T cells confers increased pulmonary arterial hypertension and vascular remodeling. , 2007, American journal of respiratory and critical care medicine.

[19]  W. Seeger,et al.  Receptor for Activated C-Kinase 1, a Novel Interaction Partner of Type II Bone Morphogenetic Protein Receptor, Regulates Smooth Muscle Cell Proliferation in Pulmonary Arterial Hypertension , 2007, Circulation.

[20]  W. Seeger,et al.  The transforming growth factor-β/Smad2,3 signalling axis is impaired in experimental pulmonary hypertension , 2007, European Respiratory Journal.

[21]  W. Seeger,et al.  Dysregulated Bone Morphogenetic Protein Signaling in Monocrotaline-Induced Pulmonary Arterial Hypertension , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[22]  M. Humbert,et al.  Fractalkine-induced smooth muscle cell proliferation in pulmonary hypertension , 2007, European Respiratory Journal.

[23]  M. Humbert,et al.  Dendritic cell recruitment in lesions of human and experimental pulmonary hypertension , 2007, European Respiratory Journal.

[24]  W. Seeger,et al.  The transforming growth factor-beta/Smad2,3 signalling axis is impaired in experimental pulmonary hypertension. , 2007, European Respiratory Journal.

[25]  N. Morrell.  Pulmonary hypertension due to BMPR2 mutation: a new paradigm for tissue remodeling? , 2006, Proceedings of the American Thoracic Society.

[26]  M. Humbert,et al.  Angiopoietin/Tie2 pathway influences smooth muscle hyperplasia in idiopathic pulmonary hypertension. , 2006, American journal of respiratory and critical care medicine.

[27]  M. Humbert,et al.  Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. , 2006, Chest.

[28]  W. Seeger,et al.  Impact of TASK-1 in Human Pulmonary Artery Smooth Muscle Cells , 2006, Circulation research.

[29]  W. Seeger,et al.  Activation of Soluble Guanylate Cyclase Reverses Experimental Pulmonary Hypertension and Vascular Remodeling , 2006, Circulation.

[30]  L. Rubin.  Pulmonary arterial hypertension. , 2006, Proceedings of the American Thoracic Society.

[31]  D. Badesch,et al.  Autoimmunity and pulmonary hypertension: a perspective , 2005, European Respiratory Journal.

[32]  W. Seeger,et al.  Transforming Growth Factor-β-Dependent Growth Inhibition in Primary Vascular Smooth Muscle Cells Is p38-Dependent , 2005, Journal of Pharmacology and Experimental Therapeutics.

[33]  W. Seeger,et al.  Reversal of experimental pulmonary hypertension by PDGF inhibition. , 2005, The Journal of clinical investigation.

[34]  A. Ziegler,et al.  Expression profiling of laser-microdissected intrapulmonary arteries in hypoxia-induced pulmonary hypertension , 2005, Respiratory research.

[35]  T. Wynn,et al.  Opposing roles for IL‐13 and IL‐13 receptor α2 in health and disease , 2004 .

[36]  M. Wills-Karp,et al.  Interleukin‐13 in asthma pathogenesis , 2004, Immunological reviews.

[37]  T. Wynn.  Fibrotic disease and the TH1/TH2 paradigm , 2004, Nature Reviews Immunology.

[38]  M. Humbert,et al.  Cellular and molecular pathobiology of pulmonary arterial hypertension. , 2004, Journal of the American College of Cardiology.

[39]  T. Wynn.  Fibrotic disease and the T(H)1/T(H)2 paradigm. , 2004, Nature reviews. Immunology.

[40]  T. Wynn,et al.  Opposing roles for IL-13 and IL-13 receptor alpha 2 in health and disease. , 2004, Immunological reviews.

[41]  T. Wynn.  IL-13 effector functions. , 2003, Annual review of immunology.

[42]  S. Narumiya,et al.  Role of prostaglandin I2 in airway remodeling induced by repeated allergen challenge in mice. , 2003, American journal of respiratory cell and molecular biology.

[43]  J. Stankova,et al.  CysLT1 receptor upregulation by TGF-beta and IL-13, but not IL-4, is associated with bronchial smooth muscle cell proliferation in response to LTD4 , 2003 .

[44]  P. Thistlethwaite,et al.  Signaling molecules in nonfamilial pulmonary hypertension. , 2003, The New England journal of medicine.

[45]  Ying Yu,et al.  PDGF stimulates pulmonary vascular smooth muscle cell proliferation by upregulating TRPC6 expression. , 2003, American journal of physiology. Cell physiology.

[46]  J. Stankova,et al.  CysLT1 receptor upregulation by TGF-beta and IL-13 is associated with bronchial smooth muscle cell proliferation in response to LTD4. , 2003, The Journal of allergy and clinical immunology.

[47]  M. Humbert,et al.  CX3C Chemokine Fractalkine in Pulmonary Arterial Hypertension , 2002 .

[48]  M. Humbert,et al.  Chemokine RANTES in severe pulmonary arterial hypertension. , 2002, American journal of respiratory and critical care medicine.

[49]  M. Yacoub,et al.  ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells. , 2002, American journal of respiratory and critical care medicine.

[50]  M. Yacoub,et al.  ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells. , 2002, American journal of respiratory and critical care medicine.

[51]  M. Humbert,et al.  CX(3)C chemokine fractalkine in pulmonary arterial hypertension. , 2002, American journal of respiratory and critical care medicine.

[52]  M. Humbert,et al.  Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. , 2001, The Journal of clinical investigation.

[53]  R. Trembath,et al.  Altered Growth Responses of Pulmonary Artery Smooth Muscle Cells From Patients With Primary Pulmonary Hypertension to Transforming Growth Factor-&bgr;1 and Bone Morphogenetic Proteins , 2001, Circulation.

[54]  Rainer M. Bohle,et al.  Real-time quantitative RT–PCR after laser-assisted cell picking , 1998, Nature Medicine.

[55]  N. Voelkel,et al.  Pulmonary hypertension and inflammation. , 1998, The Journal of laboratory and clinical medicine.

[56]  C. Thiemermann,et al.  INTERLEUKIN‐13 IS A MORE POTENT INHIBITOR OF THE EXPRESSION OF INDUCIBLE NITRIC OXIDE SYNTHASE IN SMOOTH MUSCLE CELLS THAN IN MACROPHAGES: A COMPARISON WITH INTERLEUKIN‐4 AND INTERLEUKIN‐10 , 1995, Shock.

[57]  M. Humbert,et al.  Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. , 1995, American journal of respiratory and critical care medicine.

[58]  B. Groves,et al.  Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. , 1994, The American journal of pathology.

[59]  B. Fanburg,et al.  Serotonin produces both hyperplasia and hypertrophy of bovine pulmonary artery smooth muscle cells in culture. , 1994, The American journal of physiology.

[60]  D. Stewart,et al.  Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. , 1993, The New England journal of medicine.

[61]  J. Figge,et al.  Endothelin-1 stimulates DNA synthesis and proliferation of pulmonary artery smooth muscle cells. , 1992, The American journal of physiology.